Tao Luo1, Ying Wang2, Jian Qin3, Zhi-Gang Liu4, Min Liu3. 1. Department of Anesthesiology, Peking University Shenzhen Hospital, Shenzhen, China. 2. Materials Characterization and Preparation Center, Southern University of Science and Technology, Shenzhen, China. 3. Central Laboratory, Wuhan University Renmin Hospital, Wuhan, China. 4. Department of Anesthesiology, Wuhan University Renmin Hospital, Wuhan, China.
Abstract
BACKGROUND: Exposure to pharmacological concentration of inhaled anesthetics such as isoflurane can cause short- or long-term cognitive impairments in preclinical studies. The selective antagonists of the histamine H3 receptors are considered as a promising group of novel therapeutic agents for the treatment of cognitive disorders. In this study, we investigated whether ciproxifan, a nonimidazole antagonist of H3 histamine receptors, could overcome the functional and electrophysiological sequela associated with isoflurane anesthesia. METHODS: Adult male Sprague Dawley rats were exposed to 1.4% isoflurane or vehicle gas for 2 h. The memory tests (novel object recognition and passive avoidance) as well as in vivo hippocampal excitatory synaptic potentials were recorded 24 h postanesthesia. Locomotor activity, anxiety, and nociception 24 h after isoflurane were also examined. The drugs (ciproxifan 3 mg/kg or saline) were intraperitoneally injected 30 min prior to the behavioral tests or long-term potentiation induction. RESULTS: Animals that were previously (24 h) exposed to 1.4% isoflurane for 2 h displayed no preference for novel objects and had impaired retention of a passive avoidance response at 1 h after sample phase. Treating isoflurane-exposed rats with ciproxifan significantly improved the memory performance, as evidenced by an increased discrimination ratio in objects recognition and prolonged retention time in passive avoidance test. Accordingly, hippocampus long-term potentiation was reduced in animals that received isoflurane, while administration of ciproxifan completely abolished the effect of isoflurane exposure on synaptic plasticity. Neither isoflurane nor ciproxifan altered motor performance, anxiety, and nociceptive responses. CONCLUSION: These results suggest that H3R in the CNS, probably in the hippocampus, may serve as therapeutic target for improvement of anesthesia-associated cognitive deficits.
BACKGROUND: Exposure to pharmacological concentration of inhaled anesthetics such as isoflurane can cause short- or long-term cognitive impairments in preclinical studies. The selective antagonists of the histamine H3 receptors are considered as a promising group of novel therapeutic agents for the treatment of cognitive disorders. In this study, we investigated whether ciproxifan, a nonimidazole antagonist of H3 histamine receptors, could overcome the functional and electrophysiological sequela associated with isoflurane anesthesia. METHODS: Adult male Sprague Dawley rats were exposed to 1.4% isoflurane or vehicle gas for 2 h. The memory tests (novel object recognition and passive avoidance) as well as in vivo hippocampal excitatory synaptic potentials were recorded 24 h postanesthesia. Locomotor activity, anxiety, and nociception 24 h after isoflurane were also examined. The drugs (ciproxifan 3 mg/kg or saline) were intraperitoneally injected 30 min prior to the behavioral tests or long-term potentiation induction. RESULTS: Animals that were previously (24 h) exposed to 1.4% isoflurane for 2 h displayed no preference for novel objects and had impaired retention of a passive avoidance response at 1 h after sample phase. Treating isoflurane-exposed rats with ciproxifan significantly improved the memory performance, as evidenced by an increased discrimination ratio in objects recognition and prolonged retention time in passive avoidance test. Accordingly, hippocampus long-term potentiation was reduced in animals that received isoflurane, while administration of ciproxifan completely abolished the effect of isoflurane exposure on synaptic plasticity. Neither isoflurane nor ciproxifan altered motor performance, anxiety, and nociceptive responses. CONCLUSION: These results suggest that H3R in the CNS, probably in the hippocampus, may serve as therapeutic target for improvement of anesthesia-associated cognitive deficits.
Authors: Gerard B Fox; Timothy A Esbenshade; Jia Bao Pan; Richard J Radek; Kathleen M Krueger; Betty B Yao; Kaitlin E Browman; Michael J Buckley; Michael E Ballard; Victoria A Komater; Holly Miner; Min Zhang; Ramin Faghih; Lynne E Rueter; R Scott Bitner; Karla U Drescher; Jill Wetter; Kennan Marsh; Martine Lemaire; Roger D Porsolt; Youssef L Bennani; James P Sullivan; Marlon D Cowart; Michael W Decker; Arthur A Hancock Journal: J Pharmacol Exp Ther Date: 2004-12-17 Impact factor: 4.030
Authors: R Parmentier; C Anaclet; C Guhennec; E Brousseau; D Bricout; T Giboulot; D Bozyczko-Coyne; K Spiegel; H Ohtsu; M Williams; J S Lin Journal: Biochem Pharmacol Date: 2007-01-07 Impact factor: 5.858